Advertisement
Screener

GSK plc (GLAXF) Form 6-K: Report of foreign private issuer, 2025

2.1 / 5 stars · 17/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2025-12-23: Form 6-K; Period of report 2025-12-23; Description GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US; Document a6499m.htm.
  • 2025-12-22: Form 6-K; Period of report 2025-12-22; Description DIRECTOR/PDMR SHAREHOLDING; Document a4939m.htm.
  • 2025-12-22: Form 6-K; Period of report 2025-12-22; Description TRANSACTION IN OWN SHARES; Document a3646m.htm.
  • 2025-12-19: Form 6-K; Period of report 2025-12-19; Description TRANSACTION IN OWN SHARES; Document a1943m.htm.
FiledFormPeriod of reportDescriptionDocument
2025-12-236-K2025-12-23GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN USa6499m.htm
2025-12-226-K2025-12-22DIRECTOR/PDMR SHAREHOLDINGa4939m.htm
2025-12-226-K2025-12-22TRANSACTION IN OWN SHARESa3646m.htm
2025-12-196-K2025-12-19TRANSACTION IN OWN SHARESa1943m.htm
2025-12-186-K2025-12-18TRANSACTION IN OWN SHARESa0134m.htm
2025-12-176-K2025-12-17EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDAa8507l.htm
2025-12-176-K2025-12-17TRANSACTION IN OWN SHARESa8383l.htm
2025-12-166-K2025-12-16EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVALa6711l.htm
2025-12-166-K2025-12-16TRANSACTION IN OWN SHARESa6546l.htm
2025-12-156-K2025-12-15TRANSACTION IN OWN SHARESa4641l.htm
2025-12-126-K2025-12-12DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINIONa4345l.htm
2025-12-126-K2025-12-12NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPDa4035l.htm
2025-12-126-K2025-12-12POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+a2934l.htm
2025-12-126-K2025-12-12TRANSACTION IN OWN SHARESa2856l.htm
2025-12-116-K2025-12-11BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATIONa2842l.htm
2025-12-116-K2025-12-11DIRECTOR/PDMR SHAREHOLDINGa0851l.htm
2025-12-116-K2025-12-11BLOCK LISTING APPLICATIONa0711l.htm
2025-12-116-K2025-12-11TRANSACTION IN OWN SHARESa0924lgskpos.htm
2025-12-106-K2025-12-10TRANSACTION IN OWN SHARESa9051kgskpos.htm
2025-12-106-K2025-12-10GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLCa9003kgskmsc.htm
2025-12-096-K2025-12-09DIRECTOR/PDMR SHAREHOLDINGa8719k.htm
2025-12-096-K2025-12-09TRANSACTION IN OWN SHARESa7208kgsk.htm
2025-12-086-K2025-12-08TRANSACTION IN OWN SHARESa5362kgsk.htm
2025-12-056-K2025-12-05TRANSACTION IN OWN SHARESa3573k.htm
2025-12-046-K2025-12-04TRANSACTION IN OWN SHARESa1570k.htm
2025-12-036-K2025-12-03TRANSACTION IN OWN SHARESa9639j.htm
2025-12-026-K2025-12-02TRANSACTION IN OWN SHARESa7730j.htm
2025-12-016-K2025-12-01DIRECTOR/PDMR SHAREHOLDINGa7270j.htm
2025-12-016-K2025-12-01TOTAL VOTING RIGHTSa7262j.htm
2025-12-016-K2025-12-01TRANSACTION IN OWN SHARESa5288j.htm
2025-11-286-K2025-11-28TRANSACTION IN OWN SHARESa3502j.htm
2025-11-286-K2025-11-28TRANSACTION IN OWN SHARESa1716j.htm
2025-11-266-K2025-11-26TRANSACTION IN OWN SHARESa9808i.htm
2025-11-256-K2025-11-25TRANSACTION IN OWN SHARESa8078i.htm
2025-11-246-K2025-11-24TRANSACTION IN OWN SHARESa6205i.htm
2025-11-216-K2025-11-21INITIATION OF LITIGATION AGAINST ANAPTYSBIO INCa4566i.htm
2025-11-216-K2025-11-21TRANSACTION IN OWN SHARESa4440i.htm
2025-11-206-K2025-11-20TRANSACTION IN OWN SHARESa2573i.htm
2025-11-196-K2025-11-19TRANSFER OF TREASURY SHARESa0711i.htm
2025-11-196-K2025-11-19TRANSACTION IN OWN SHARESa0686i.htm
2025-11-186-K2025-11-18DIRECTOR/PDMR SHAREHOLDINGa0424i.htm
2025-11-186-K2025-11-18TRANSACTION IN OWN SHARESa8822h.htm
2025-11-176-K2025-11-17TRANSACTION IN OWN SHARESa6865h.htm
2025-11-146-K2025-11-14TRANSACTION IN OWN SHARESa4995h.htm
2025-11-136-K2025-11-13DIRECTOR/PDMR SHAREHOLDINGa4607h.htm
2025-11-136-K2025-11-13TRANSACTION IN OWN SHARESa3150h.htm
2025-11-126-K2025-11-12BLOCK LISTING INTERIM REVIEWa2717h.htm
2025-11-126-K2025-11-12TRANSACTION IN OWN SHARESa1413h.htm
2025-11-126-K2025-11-12TRANSACTION IN OWN SHARESa9459g.htm
2025-11-106-K2025-11-10GSK PUBLISHES PROVISIONAL DIVIDEND DATESa7768g.htm
2025-11-106-K2025-11-10TRANSACTION IN OWN SHARESa7622g.htm
2025-11-076-K2025-11-07TRANSACTION IN OWN SHARESa5775g.htm
2025-11-066-K2025-11-06TRANSACTION IN OWN SHARESa3823g.htm
2025-11-056-K2025-11-05TRANSACTION IN OWN SHARESa1864g.htm
2025-11-046-K2025-11-04TRANSACTION IN OWN SHARESa0071g.htm
2025-11-036-K2025-11-03TOTAL VOTING RIGHTSa9666f.htm
2025-11-036-K2025-11-03TRANSACTION IN OWN SHARESa7775f.htm
2025-10-316-K2025-10-31TRANSACTION IN OWN SHARESa5829f.htm
2025-10-306-K2025-10-30DIRECTOR/PDMR SHAREHOLDINGa5627f.htm
2025-10-306-K2025-10-30TRANSACTION IN OWN SHARESa3983f.htm
2025-10-296-K2025-10-29TRANSACTION IN OWN SHARESa1913f.htm
2025-10-296-K2025-10-293RD QUARTER RESULTSa1902f-gskoriginaledgar.htm
2025-10-286-K2025-10-28TRANSACTION IN OWN SHARESa0106f.htm
2025-10-286-K2025-10-28GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EUa9876e.htm
2025-10-276-K2025-10-27TRANSACTION IN OWN SHARESa8292e.htm
2025-10-246-K2025-10-24BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMAa6592e.htm
2025-10-246-K2025-10-24TRANSACTION IN OWN SHARESa6520e.htm
2025-10-236-K2025-10-23TRANSACTION IN OWN SHARESa4624e.htm
2025-10-226-K2025-10-22POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDIa2969e.htm
2025-10-226-K2025-10-22TRANSACTION IN OWN SHARESa2955e.htm
2025-10-226-K2025-10-22LATOZINEMAB DATA READ OUTa2946e.htm
2025-10-216-K2025-10-21POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFSa1154e.htm
2025-10-216-K2025-10-21TRANSACTION IN OWN SHARESa1048e.htm
2025-10-216-K2025-10-21GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBRa1483e.htm
2025-10-206-K2025-10-20TRANSACTION IN OWN SHARESa9163d.htm
2025-10-176-K2025-10-17TRANSACTION IN OWN SHARESa7391d.htm
2025-10-166-K2025-10-16DIRECTOR/PDMR SHAREHOLDINGa6865d.htm
2025-10-166-K2025-10-16TRANSACTION IN OWN SHARESa5620d.htm
2025-10-156-K2025-10-15DIRECTOR/PDMR SHAREHOLDINGa4798d.htm
2025-10-156-K2025-10-15TRANSACTION IN OWN SHARESa3746d.htm
2025-10-146-K2025-10-14GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINAa1855d.htm
2025-10-146-K2025-10-14TRANSACTION IN OWN SHARESa1776d.htm
2025-10-146-K2025-10-14DIRECTOR/PDMR SHAREHOLDINGa1589d.htm
2025-10-146-K2025-10-14TRANSACTION IN OWN SHARESa9907c.htm
2025-10-106-K2025-10-10DIRECTOR/PDMR SHAREHOLDINGa9741c.htm
2025-10-106-K2025-10-10TRANSACTION IN OWN SHARESa8130c.htm
2025-10-096-K2025-10-09TRANSACTION IN OWN SHARESa6347c.htm
2025-10-086-K2025-10-08TRANSACTION IN OWN SHARESa4535c.htm
2025-10-076-K2025-10-07TRANSACTION IN OWN SHARESa2743c.htm
2025-10-066-K2025-10-06TRANSACTION IN OWN SHARESa0832c.htm
2025-10-036-K2025-10-03TRANSACTION IN OWN SHARESa9057b.htm
2025-10-026-K2025-10-02TRANSACTION IN OWN SHARESa7193b.htm
2025-10-016-K2025-10-01TOTAL VOTING RIGHTSa6734b.htm
2025-10-016-K2025-10-01TRANSACTION IN OWN SHARESa5053b.htm
2025-09-306-K2025-09-30GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMMEa3115b.htm
2025-09-296-K2025-09-29GSK APPOINTS CEO DESIGNATEa1108b.htm
2025-09-226-K2025-09-22DIRECTOR/PDMR SHAREHOLDINGa2998a.htm
2025-09-196-K2025-09-19TRANSACTION IN OWN SHARESa9586z.htm
2025-09-186-K2025-09-18TRANSACTION IN OWN SHARESa7761z.htm
2025-09-176-K2025-09-17GSK US INVESTMENT ANNOUNCEMENTa6046z.htm
Advertisement